Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock Has Consensus Target Price of $40.86

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $40.86.

LYEL has been the subject of several analyst reports. Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. HC Wainwright restated a “buy” rating on shares of Lyell Immunopharma in a report on Friday, September 11th. Royal Bank Of Canada set a $34.00 price objective on shares of Lyell Immunopharma in a research report on Friday, August 14th. Wall Street Zen upgraded shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Finally, Stifel Nicolaus assumed coverage on Lyell Immunopharma in a report on Thursday, August 6th. They issued a “buy” rating and a $36.00 target price on the stock.

Lyell Immunopharma Price Performance

LYEL stock opened at $8.79 on Friday. The firm has a market capitalization of $215.35 million, a P/E ratio of -0.69 and a beta of -0.03. The business’s 50-day moving average is $12.61 and its two-hundred day moving average is $15.52. Lyell Immunopharma has a 1 year low of $8.21 and a 1 year high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%.The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. On average, analysts expect that Lyell Immunopharma will post -7.16 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Velan Capital Investment Management LP grew its position in shares of Lyell Immunopharma by 2.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after buying an additional 3,000 shares during the last quarter. BBR Partners LLC purchased a new stake in Lyell Immunopharma in the fourth quarter valued at $210,000. Walleye Capital LLC purchased a new stake in Lyell Immunopharma in the first quarter valued at $445,000. Squarepoint Ops LLC boosted its stake in Lyell Immunopharma by 119.4% in the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after acquiring an additional 23,028 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Lyell Immunopharma in the second quarter valued at $347,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for cancer, with an emphasis on solid tumors. The company seeks to address limitations of existing cell therapies, including T-cell exhaustion, limited persistence and reduced activity within the tumor microenvironment.

Lyell uses cell-engineering and genomic technologies to develop investigational chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapies.